<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Mika Wang 王美华 on Medium]]></title>
        <description><![CDATA[Stories by Mika Wang 王美华 on Medium]]></description>
        <link>https://medium.com/@mikastefanie?source=rss-e928e5144b97------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/0*l4E23agILfQpVdb5.jpg</url>
            <title>Stories by Mika Wang 王美华 on Medium</title>
            <link>https://medium.com/@mikastefanie?source=rss-e928e5144b97------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Fri, 20 Nov 2026 16:51:03 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@mikastefanie/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[My pregnancy and birth cost over $100K (and I was healthy, delivered vaginally, without anesthesia)]]></title>
            <link>https://medium.com/@mikastefanie/my-pregnancy-and-birth-cost-over-100k-and-i-was-healthy-delivered-vaginally-without-anesthesia-7f5d6bf3a779?source=rss-e928e5144b97------2</link>
            <guid isPermaLink="false">https://medium.com/p/7f5d6bf3a779</guid>
            <category><![CDATA[pregnancy]]></category>
            <category><![CDATA[us-health-care]]></category>
            <category><![CDATA[healthcare-costs]]></category>
            <category><![CDATA[birth]]></category>
            <category><![CDATA[delivery]]></category>
            <dc:creator><![CDATA[Mika Wang 王美华]]></dc:creator>
            <pubDate>Fri, 14 Jan 2022 05:21:16 GMT</pubDate>
            <atom:updated>2022-01-14T05:21:16.634Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*i650dYdaCwpc4refCzjCAA.png" /><figcaption>Payer and Patient Responsibility across multiple care categories (primary care, specialists, labs, inpatient care)</figcaption></figure><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=7f5d6bf3a779" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Chasing Startup Success: Is there a Magic Formula?]]></title>
            <link>https://medium.com/@mikastefanie/chasing-startup-success-is-there-a-magic-formula-2e8cb10a9ef0?source=rss-e928e5144b97------2</link>
            <guid isPermaLink="false">https://medium.com/p/2e8cb10a9ef0</guid>
            <category><![CDATA[data-visualization]]></category>
            <category><![CDATA[startup]]></category>
            <category><![CDATA[vc]]></category>
            <category><![CDATA[data-analysis]]></category>
            <dc:creator><![CDATA[Mika Wang 王美华]]></dc:creator>
            <pubDate>Fri, 14 Jan 2022 05:18:18 GMT</pubDate>
            <atom:updated>2022-01-14T05:18:18.006Z</atom:updated>
            <content:encoded><![CDATA[<h3>Problem Statement</h3><p>Many have tried to crack the “magical formula” of fundraising success, yet, is fundraising an art or a science? As a VC, which startups are more likely to generate revenue and, ultimately, exit? As an entrepreneur, am I more likely to succeed in raising equity funding (or exit) if I pursue certain industries, base my team in certain geographies, or even attend specific universities?</p><p>Several studies have attempted to evaluate startup success and the factors that underlie significant variations in startup outcomes (e.g., <a href="https://startupgenome.com/reports">Startup Genome Report</a>). What is missing, however, is a comprehensive analysis of a variety of startup and founder characteristics that leads to revenue generation and, ultimately, a company exit. Our analysis aims to understand the characteristics that lead to success. Specifically, we have two objectives:</p><ol><li>to evaluate the factors that impact exit status and revenue generation for a given startup, and</li><li>to evaluate the factors that impact startup equity funding (total amount of USD), and to identify the company characteristics that are more likely to lead to equity funding, the lifeline for early stage companies.</li></ol><p>In order to achieve these objectives, we ask a number of key questions on each side of the fundraising coin. In evaluating targets from the VC perspective, key questions include: which startups are more successful (i.e., generate more revenue, exit)? What characteristics lead to greater revenue generation? What is the likelihood of a startup company’s exit, given tangible characteristics including number of founders, alumni affiliations, years since founding, and region/location? Are founders from certain schools more likely to exit, and what is the comparison between alumni founders from the Stanford Graduate School of Business (GSB), Harvard Business School (HBS) and other schools? Does it really make sense to target and perhaps settle for less attractive terms in order to secure a coveted GSB/HBS founder? Finally, are we able to predict how much revenue a company may generate?</p><p>Key questions as an entrepreneur include: how much equity funding will I raise (based on my characteristics, e.g., alumni affiliation, HQ, number of founders, revenue generated)? Given my characteristics, how likely am I to raise a certain amount of funding? What is the effect of attending certain universities (GSB, HBS) and will I raise more funding having gone to these prestigious schools?</p><h3>Stakeholders</h3><p>When doing our analysis, we felt it was important to look at two stakeholders perspectives — Venture Capitalists (VCs), who are the main type of investors into the ventures, and the Entrepreneurs (founders and operators) as the principle risk takers of these ventures.</p><h3>Principal Findings</h3><p>Based on our regression analysis, we have identified the following key findings.</p><p>For VCs, age of company significantly impacts likelihood of company exit (companies greater than or equal to 10 years since founding are significantly more likely to exit). Founders also matter. While diversity among the founding team seems to be negatively correlated with exit, university affiliation (alma mater) matters. Attending HBS or GSB significantly increases the likelihood of a company exit. Finally, revenue generation, and existence of company patents also significantly improve the likelihood of exit. This is all great news for VCs looking to invest in companies that stand out in these characteristics when other characteristics are held equal.</p><p>Number of founders significantly impacts the amount of startup funding, and diversity (apart from women founded) has minimal impact on determining whether startups are able to raise funding. In addition, we compared GSB, HBS and “other” startups (entrepreneurs who are alumni of these schools) and found that Stanford/Harvard Graduates are more likely to make an exit and attract higher rounds as well as total amount of funding.</p><h3>Recommendations</h3><p>Based on our analysis, we offer a few recommendations to VCs optimizing for company exit: invest in founders who have graduated from HBS or GSB (in that order), companies with patents, and companies headquartered in the U.S., as these characteristics all significantly increase likelihood of exit. Additionally, and perhaps somewhat self-evident, companies founded 10 or more years ago are affiliated with a higher likelihood of an exit.</p><p>For entrepreneurs chasing startup success (i.e., equity funding, revenue), we offer four recommendations. Recruit co-founders from elite schools such as Stanford GSB or HBS, as it will improve your chances of exiting as well as having a higher valuation. Having multiple co-founders will increase your likelihood of an exit. Base the company HQ in the U.S. whenever plausible, as it will also improve your chances of an exit. Developing a strong patents pipeline and adding technology in your venture will both increase the amount of funding you can raise.</p><h3>Project Methodology</h3><h3>Data Sources and Descriptive Analysis</h3><p>Our data is pulled from Crunchbase, which is one of the most comprehensive datasets on startups, and is used by most VC firms and investors. We secured a dataset including 2,723 companies established across industries in the past 30 years. This data also includes the founder’s alma mater (GSB / HBS / other), demographics (founder diversity, geographic location), and success criteria (total funding raised, exit status, number of funding rounds, etc.).</p><p>In terms of geographic representation, we have 1849 (67.9%) of companies headquartered in the United States. For our analysis, we grouped companies into five regions: United States, EU, APAC, Latin America and the Gulf Cooperation Council (as we have two proud Middle Easterners in the group). Here is a representation by country:</p><p>Chart 1.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/600/0*I26rPVIeJY8EMVdQ" /></figure><p>In grouping regions, we also explored exit status by HQ location and found, perhaps unsurprisingly, that the U.S. has the greatest proportion of exits (24.4% of U.S. headquartered companies have exited). The next is APAC-headquartered companies (13.9%) followed by EU-headquartered companies (12.4%) and Latin American-headquartered companies (5.9%), with no exits recorded for GCC-headquartered companies (0 of 8 companies):</p><p>Chart 2.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*IXqGmjrNm7tGI4_O" /></figure><p>As we know that less than 3% of VC funding goes to women and minority founded companies, we were also curious to look at exit status by diversity status. Here we define founder diversity as companies that are either women founded or women led, or minority (e.g., black-american, hispanic, east asian, south asian) founded or minority led. By exit status, we do not see a clear difference:</p><p>Chart 3.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*SGhZfMxUnigT95Gs" /></figure><p>Looking at founder diversity status more deeply, we see there is a slight increase in percentage of diverse founders amongst companies &lt; 10 years vs. companies &gt; 10 years. This may reflect the increased focus in diversity representation, particularly the diversity &amp; inclusion efforts of recent years:</p><p>Chart 4.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*9Oj4x6h4uaxawtwA" /></figure><p>Another factor we evaluate is patent status (i.e., whether the company has secured a patent). We will include this in our multivariate regression to look at whether the company has secured a patent (0/1) and, if so, the number of patents (linear variable) affect likelihood of company exit. From the chart below, we see that having a patent is much more common amongst exited companies (27.4% of exited companies have patents, vs. 10% of non-exited companies have patents):</p><p>Chart 5.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*PRr_4iov1WkXwy41" /></figure><p>Finally, linked to our secondary objective of understanding more recent trends among startups, we also explored whether exit status differs by company age:</p><p>Chart 6.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/966/0*Zxt-shkP24gylTs0" /></figure><p>As expected, we see that a greater proportion of exits are for companies &gt; 10 years. Only 32.2% of exited companies are less than 10 years of age, while 65.4% of non-exited companies are less than 10 years of age.</p><p>We also explored revenue generation. We looked at patent status (0/1) and revenue, and found that companies with patents generated greater revenues, on average, than companies without patents. For companies with patents, average revenue generated was $213.2M, while for companies without patents, average revenue generated was only $31.2M.</p><p>Exploring exit status and revenue, we found that average revenue for exited companies was $209.6M, while non-exited companies had an average revenue of $32.8M. This is expected, as VCs often look for traction (generating revenue) as a key criterion for investing in companies they believe will exit with some return.</p><h3>Identified Y &amp; X Variables</h3><p>After a thorough data exploration, we identified the following to be the best variables with which we would focus our analyses. For VCs, we looked at the following:</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*ljqCP2RHLCQhcW1LhbXXJw.png" /></figure><p>For the Entrepreneurs, we looked at what factors influence company revenue, what factors influence number of funding rounds, and what factors influence total amount of funding (USD):</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*r50BstGYDG_lflkiCZBY6g.png" /></figure><h3>Analysis and Discussion</h3><h3>Venture Capitalist (VC) Perspective</h3><p>As a VC, return is realized upon exit of an investment. According to a16z, a venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz, roughly 60% of investments fail to return any value, with approximately 20% of investments generating blockbuster returns. The problem for the VC, then, is to identify factors that are likely to increase the chance of an exit. In this section, we evaluate company factors that impact exit status with a secondary objective of understanding changes in startup trends by evaluating companies founded within the last 10 years versus those founded 10 or more years ago.</p><h3>Objectives</h3><p>Our primary objective is to identify factors that are likely to increase the chance of an exit. Our secondary objective is to build a model that can predict exit status with greatest accuracy.</p><h3>What factors impact exit status most?</h3><p>We first investigate factors that impact exit status:</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*-V1AW6ra2pm04x0A" /></figure><p>We can interpret the coefficients as follows:</p><ul><li>The Y-intercept is significant at the 1% (even significant at the .1%) level, with a coefficient of 0.2308; the Y-intercept is the expected mean value of Exit.Status when all X-variables = 0. This is more meaningful when we have dummy variables with 0 or 1 (including University, Diversity, Patents). So when a company’s founders attend HBS, number of founders = 0 (impossible), no Full Time Employees (FTE), no Revenue, no diversity, and no patents, then the exit status likelihood is 23%. This is the baseline from which everything else will change.</li><li># Full Time Employees (FTE) is also significant at the 1% level, increasing the exit likelihood of a company by .000051 percentage points (since exit.status is a dummy variable of 0 or 1) for every incremental 1 person increase in FTE.</li><li>Finally, a company’s patent status is significant at the 1% level, and companies with patents (so a status of 1) increase the likelihood of exit by 15.8 percentage points when all the other variables are held constant.</li></ul><h3>Can we predict an exit?</h3><p>Next, we build a logistic regression model in order to model the dichotomous outcome variables of exit status (where 0 = not exited or shut down, 1 = acquired or IPO).</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*Z3eMRc7aCu3mH9oA" /></figure><p>From the coefficients, we see company age (less than 10 years), having patents, number of founders, and HQ in the U.S. are statistically significant at the .1% level. Specifically, we note:</p><ul><li>For dummy patents (a 0/1 value), having patents increases the log odds of a company exit (versus non exit) by 0.76.</li><li>For a one unit increase in number of founders (e.g., from 1 to 2 founders), the log odds of exiting increases by 0.22.</li><li>Having the company HQ in the U.S., versus having HQ ex-U.S., increases the log odds of exit by 1.23!</li></ul><p>Next, we wanted to see odds ratio and confidence intervals for the coefficient estimates:</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/948/0*f4tWIXtT4ptzf4hX" /></figure><p>We can see that having patents increase the odds of a company exit by a factor of 2.13, while having a founder who attended the GSB increases the odds of a company exit (versus not exiting) by a factor of 0.83. In other words, compared to HBS, the chance of a company exit with a GSB alumni founder is 17% less. Compared to HBS, the chance of a company exit with a non-GSB, non-HBS founder is 32% less.</p><p>Next we look at company age, number of patents granted, number of founders and diversity:</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1002/0*iGdAxXe8M65ymI4-" /></figure><p>regVC = lm(Exit.Status ~ Company.Age + IPqwery…Patents.Granted + Number.of.Founders + Diversity, data = dfGSB)</p><p>summary(regVC)</p><p>plot(regVC, 1)</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*2FxSL43HPhQXFaCT" /></figure><p>We can interpret the coefficients and residuals plots as following:</p><ul><li>Company age is significantly correlated with an increase in exit likelihood for a company. For every 1 year increase in company age, likelihood of exit status increases by 2.6 percentage points.</li><li>Interestingly, we see a negative correlation (though not significant) with diversity of the founding team, which we will dig into later. Makes sense as less than 3% of VC funding goes into women or minority owned/led companies, and only recently has this been a focus area.</li><li>Our residual plot does not look good, as we can see a clear pattern, points are not randomly scattered, and we see outliers. However, with a binomial outcome variable (exit.status = 0 or 1), it doesn’t make sense to look at residual plots.</li></ul><p>We then look at prediction models to see whether we can predict if a company will exit based on certain characteristics. We built 5 prediction models, and the lowest RMSE we found was 0.396. The naive model had an RMSE of 0.407.</p><p>Model 3 had the lowest RMSE, indicating the best fit and predictive ability for exit status:</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*WVjp0IdkgsJGhv_P" /></figure><p>Here, age (greater than 10 years), having patents, having a greater number of founders, and attending HBS (or GSB, but not significant), are all positively associated with a greater likelihood of exiting.</p><p>We experimented on a predictive model looking at Revenue, Industry (dummy), HQ Geography and we are able to lower RMSE slightly. However we do not find a healthy residual plot.</p><p>Model6 = lm(Exit.Status ~ RevClean + Dummy…Healthcare + Dummy…US + Dummy…GCC + Dummy…Latin.America, data = dfTrain)</p><p>summary(Model6)</p><p>dfPredictNew = predict(Model6, newdata = dfTest)</p><p>summary(dfPredictNew)</p><p>sqrt(mean((dfTest$Exit.Status-dfPredictNew)² , na.rm = TRUE))</p><p>plot(Model6,1)</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/942/0*x_BDr7ooXgWNe9gU" /></figure><p>RMSE:</p><p>&gt; sqrt(mean((dfTest$Exit.Status-dfPredictNew)² , na.rm = TRUE))</p><p>[1] <strong>0.3893103</strong></p><h3>Does Stanford or Harvard make a difference to your likelihood to exit?</h3><p>Based on the data we have (see data section), you can see some coefficients below:</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*qNem3yfmUkSMZKwq" /></figure><p># Change the baseline for universities</p><p>dfAllFactored &lt;- dfAll %&gt;%</p><p>mutate(University = relevel(factor(University), ref = “Other”))</p><p># Does having a stanford university certificate be more likely that I’ll get an exit?</p><p>regEnt1 = lm(Exit.Status ~ factor(University), data = dfAllFactored)</p><p>summary(regEnt1)</p><p>plot(regEnt1,1)</p><p>Based on the above, you can see that:</p><ul><li>Harvard graduates have a 10% more likelihood of getting an exit than “Other” Non Stanford/Harvard founders</li><li>Stanford graduates have an 11% more likelihood of getting an exit as a founder than “Other” non Stanford/Harvard founders</li></ul><h3>Entrepreneurs Perspective</h3><h3>Problem Statement</h3><p>As an entrepreneur, the holy-grail for many entrepreneurs is to find the right founders, build a startup, generate significant revenue, raise the valuation as much as possible, and ultimately, to exit.</p><h3>Objectives</h3><p>As part of this, we looked at a number of factors not already covered in the VC section, that might show a correlation between the secret sauce &amp; magic to entrepreneurial success.</p><h3>What factors impact Total Amount Raised?</h3><p>The survival of a startup is strongly linked to how much money the startup can raise. Our analysis shows the following correlation:</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*HwFpDfN9NTZCwWnf" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*f0XPt3XATvi9YRCm" /></figure><p>newReg = lm(log(Total.Funding.Amount.Currency..in.USD.) ~</p><p>factor(University) +</p><p>Number.of.Founders +</p><p>BuiltWith…Active.Tech.Count +</p><p>factor(HQRegion) +</p><p>Dummy…Healthcare +</p><p>Dummy…Patents +</p><p>AgeLessThan10,</p><p>data = dfAllFactored2)</p><p>summary(newReg)</p><p>plot(newReg,1)</p><p>This result helped us answer a number of additional questions</p><h4>Does Stanford or Harvard make a difference on the amount raised?</h4><ul><li>Having an entrepreneur from Stanford GSB increases funding by 104%</li><li>Having an entrepreneur from Harvard GSB increases funding by 97%</li></ul><h4>Does Number of founders impact the amount raised?</h4><ul><li>Yes, increasing founders by 1, increases funding by 21%. There must be an inflection point (e.g., after 3, the increase in funding decreases), which we will explore (see Appendix).</li></ul><h4>Does adding technology increase the amount of funding raised?</h4><ul><li>It seems so. Adding a new technology increases funding by 2.6%. However, keep in mind that this might be that inverse causality — where more funding increases funding.</li></ul><h4>Does the region increase the amount of funding raised?</h4><ul><li>Compared to the US, companies with their headquarters in the Asia Pacific region raise 67% more funding. Note that this is likely due to the data source. Fewer APAC based companies are tracked (compared to the U.S.), and the ones that are, are likely to raise more equity funding, have more PR etc.</li><li>Compared to the US, companies with their headquarters in the EU raises 71% less funding</li></ul><h4>Does healthcare as an industry impact funds raised?</h4><ul><li>Yes, this increases funding by 43%. This makes sense as several biotech or pharma companies require extensive funding to even launch a single product.</li></ul><h4>Do patents matter?</h4><ul><li>Having at least one patent can increase funding by 127%. This makes sense as companies with defensible patents build a moat, which can be attractive to VCs.</li></ul><p>Data and Analysis compiled in conjunction with my GSB MSx ’22 classmates:</p><ul><li>Mashary AlShaman</li><li>Marshal Pang</li><li>Moe El Tanahy</li><li>Chloe Zhu</li></ul><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=2e8cb10a9ef0" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Pregnancy in the time of corona]]></title>
            <link>https://medium.com/@mikastefanie/pregnancy-in-the-time-of-corona-eb5c3b6f8f62?source=rss-e928e5144b97------2</link>
            <guid isPermaLink="false">https://medium.com/p/eb5c3b6f8f62</guid>
            <category><![CDATA[pregnancy]]></category>
            <category><![CDATA[moms]]></category>
            <category><![CDATA[covid19]]></category>
            <category><![CDATA[mompreneur]]></category>
            <dc:creator><![CDATA[Mika Wang 王美华]]></dc:creator>
            <pubDate>Sun, 29 Mar 2020 23:03:32 GMT</pubDate>
            <atom:updated>2020-03-29T23:03:32.949Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/500/1*ciMxSJdz60g_7KdfMQiTDA@2x.jpeg" /></figure><p>It was on the first Sunday of 2020 after my husband and I had just settled in after a wonderful holiday trip home to Japan that I saw a faint, second line slowly start to appear on the pregnancy test below me. Was it just an evaporation line? Is my jetlagged mind playing tricks on me? Seven (increasingly positive) tests later, it was clear the tests were not faulty and, while still very jetlagged, my mind was quite accurately interpreting my new pregnant condition.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/858/1*3uiXG3cehf3GnPEHL-UWEQ@2x.jpeg" /></figure><p>Less than 8 weeks later, as our growing baby reached the size of a strawberry and began to develop nail beds, Japan became the second country to be upgraded to a level two advisory and the COVID-19 outbreak was now officially a pandemic.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*qLIMqWP_BEr8fj9l4z83-w@2x.jpeg" /></figure><p>First, the gratitude. Our families (in Japan and the U.S., or in the case of my father, likely on his way from one to the other) have thankfully stayed safe and healthy throughout. Out of an abundance of caution, my husband’s family holed up early on and, despite the lack of lockdown in the early days, largely stayed away from public transportation, the city’s arteries and veins that efficiently distribute its residents throughout. They stayed away from crowded restaurants and bars and have even forgone the beautiful hanami cherry-blossom viewing that the country prides itself on. Instead, they’ve donned masks and gloves and gone for daily walks, kept to a strict routine and haven’t seen my husband’s ninety plus year-old grandmother, who lives at a nearby elderly home, for months out of fear of transmitting the coronavirus to those most at-risk. After a work trip to Macau just a week before Hong Kong began to report initial coronavirus cases, my father has been grounded, for perhaps his longest non-travel streak in decades. My mother, heavily involved in her local community, has given up church, tutoring, language lessons and group yoga — and is safely quarantined an hour south of us.</p><p>Our second trimester screening was earlier in the week. We could tell our OBGYN was on edge. “Extra hugs next time!” she promised, before letting us know that ‘next time’ would not be at our scheduled antenatal visit, but rather in two months time, “to limit non-essential visits” and mitigate risk of spreading the virus to us women now considered to be vulnerable (according to the U.K.’s <a href="https://www.rcog.org.uk/globalassets/documents/guidelines/2020-03-26-covid19-occupational-health.pdf">Royal College of Obstetrics and Gynecology</a>). Friends in NY have told us that partners are no longer allowed in hospitals during delivery. While this makes perfect sense from a risk-perspective, I selfishly hope to avoid having to deliver alone.</p><p>Every morning I walk my dogs at 6:40am before the slew of WebEx meetings and each night, around 9pm, I unscrew the cap of my quickly dwindling jar of prenatals to open a packet and swallow my 6 pills that help keep our baby nourished. If I happen to fall asleep and forget, I often wake up and rush upstairs to make sure I’m supplementing the nutrients the human growing inside me needs. The morning walk and evening prenatals are just two of the small rituals that have brought an unexpected level of comfort amidst a morphing backdrop.</p><p>During the next several months, I will share relevant research, tips from experts, best practices to keep your mind, body and spirit healthy and (hopefully not too many) snaps of my latest baking creations. Stay strong, fellow mamas-to-be and look forward to the light(s) at the end of the tunnel. We are in this together!</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=eb5c3b6f8f62" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Liquid Biopsy — enabling non-invasive precision medicine through a simple blood sample]]></title>
            <link>https://medium.com/@mikastefanie/liquid-biopsy-enabling-non-invasive-precision-medicine-through-a-simple-blood-sample-6707184d4600?source=rss-e928e5144b97------2</link>
            <guid isPermaLink="false">https://medium.com/p/6707184d4600</guid>
            <category><![CDATA[health]]></category>
            <category><![CDATA[cancer]]></category>
            <category><![CDATA[biotechnology]]></category>
            <category><![CDATA[oncology]]></category>
            <category><![CDATA[diagnostic-testing]]></category>
            <dc:creator><![CDATA[Mika Wang 王美华]]></dc:creator>
            <pubDate>Thu, 13 Dec 2018 02:39:57 GMT</pubDate>
            <atom:updated>2018-12-13T02:39:57.516Z</atom:updated>
            <content:encoded><![CDATA[<h3>Liquid Biopsy — enabling non-invasive precision medicine through a simple blood sample</h3><iframe src="https://cdn.embedly.com/widgets/media.html?src=https%3A%2F%2Fwww.youtube.com%2Fembed%2FfPKqtPcPvd4%3Ffeature%3Doembed&amp;url=http%3A%2F%2Fwww.youtube.com%2Fwatch%3Fv%3DfPKqtPcPvd4&amp;image=https%3A%2F%2Fi.ytimg.com%2Fvi%2FfPKqtPcPvd4%2Fhqdefault.jpg&amp;key=a19fcc184b9711e1b4764040d3dc5c07&amp;type=text%2Fhtml&amp;schema=youtube" width="854" height="480" frameborder="0" scrolling="no"><a href="https://medium.com/media/0352199e3f72e9110958ae0532ef1bc2/href">https://medium.com/media/0352199e3f72e9110958ae0532ef1bc2/href</a></iframe><p>According to the NCI, a liquid biopsy is a “test done on a sample of blood to look for cancer cells from a tumor that are circulating in the blood or for pieces of DNA from tumor cells that are in the blood.” Liquid biopsies can be used across the patient journey, from early detection (generally requiring large panel sizes or ultra-deep sequencing) through diagnosis, treatment selection and monitoring, and surveillance for disease recurrence.</p><p>Though an estimated~1% of tumors are sequenced today, with a much smaller fraction done using liquid biopsy, we anticipate this field will explode, with the liquid biopsy manufacturing market (i.e., sales of kits and reagents, excluding sales of platforms and/or services) surpassing $1B by 2023.</p><p>What does this mean for patient care? Liquid biopsies offer three key advantages over traditional tissue testing:</p><ul><li>Non-invasive (i.e., the only option for the ~15% of advanced-stage lung cancer patients with no resectable tissue)</li><li>Overcomes issues associated with tumor heterogeneity (i.e., one section of tumor tissue may look very different, genomically speaking, than another section of tissue)</li><li>Ease-of-use (easy sample collection enabling serial monitoring)</li></ul><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*UH3NR3ahOs6JKjzVcZXWLg.png" /><figcaption>Source: <a href="http://decibio.com/">DeciBio</a></figcaption></figure><p>While tissue testing continues to be the gold-standard for cancer diagnostics, liquid biopsy has gained ground quickly. There are over 100 companies today offering liquid biopsy products, from Freenome’s Adaptive Genomics Engine which combines AI and machine-learning with biomarker detection to identify cancer before symptoms begin, to Guardant Health’s G360, a 73-gene assay that guides optimal treatment for metastatic non-small cell lung cancer patients.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*AGt4fZ7rVjwLZ2OaYrYrXw.png" /><figcaption>Source: DeciBio <a href="https://www.decibio.com/resource_library/liquid-biopsies-key-transforming-cancer-care/">Liquid Biopsy White Paper</a></figcaption></figure><p>Given the level of investment activity (&gt;$4B poured into the liquid biopsy space over the past few years, with GRAIL, Guardant Health, and Tempus Labs as the pure-play liquid biopsy providers leading the way), we anticipate a market shakeout in the next 1–2 years leaving only 10–14 players left to serve patients with a blood-based diagnostic offering.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*i6izHYG6AFm_oj2XQXKoKQ.png" /><figcaption>Source: DeciBio <a href="https://www.decibio.com/intelligence/liquid-biopsy-fad-or-the-future-market-report-coming-2018/">Liquid Biopsy Market Report</a></figcaption></figure><p>From taking a multi-modal technological approach (e.g., combining genomics and proteomics, like John Hopkins spin-out <a href="https://papgeneinc.com/">PapGene</a>) to analyzing a variety of biomarkers beyond the traditional three (i.e., circulating tumor DNA / RNA, circulating tumor cells, and exosomes), new entrants are taking increasingly innovative approaches in order to differentiate — and attract investor funding. Investing in an industry with a history of <a href="https://www.usatoday.com/story/money/business/2018/09/05/theranos-blood-testing-company-dissolve/1199850002/">blood-based diagnostic drama</a>, should investors be worried?</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/528/1*zFtHEviKt2F-BCpFFGr8fQ.png" /><figcaption>Source: DeciBio <a href="https://www.decibio.com/intelligence/liquid-biopsy-fad-or-the-future-market-report-coming-2018/">Liquid Biopsy Market Report</a></figcaption></figure><p>Not if the companies are complying with guidelines, publishing in peer-reviewed journals and demonstrating analytical and clinical validity, according to regulators. In fact, a slew of companies — including Guardant Health, Foundation Medicine, Personal Genome Diagnostics (PGDx) and PapGene have all received <a href="https://www.fda.gov/medicaldevices/deviceregulationandguidance/howtomarketyourdevice/ucm441467.htm">Breakthrough Device Designation</a> (BDD) from the U.S. Food and Drug Administration (FDA) indicating these liquid biopsy providers “<em>provide for more effective diagnosis for life-threatening or irreversibly debilitating diseases, for which no approved or cleared treatment exists or that offer significant advantages over existing approved or cleared alternatives.”</em></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*1He_BEsOB0hWMgZA.jpg" /><figcaption>Source: Personal Genome Diagnostics (PGDx); the company’s PGDx Elio Plasma Resolve cell-free DNA assay received a Breakthrough Device Designation from the FDA in July 2018.</figcaption></figure><p>What does the future look like for liquid biopsy? In a few years, will we all be dropping blood samples off at a local Walgreens or ordering a testing kit through Amazon Prime to ensure we are still cancer-free? What happens when traces of cancer are detected, and will it lead to preemptive treatment interrupting our bodies’ natural defense? What happens when a mutation is detected, but there is no targeted therapy available (or accessible due to local regulatory or reimbursement constraints)?</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/470/0*BSRLzwXB_JzXOPp7.jpg" /><figcaption>Source: <a href="https://www.pinterest.com/pin/368732288210953658/?lp=true">Pinterest</a></figcaption></figure><p>If you’re interested in following developments in the field, sign up for <a href="https://decibio.us16.list-manage.com/subscribe?u=e16a4bbb47de922693a7e138a&amp;id=8c04e2abda">weekly liquid biopsy news</a>. If you want market data, check out <a href="https://www.decibio.com/intelligence/liquid-biopsy-fad-or-the-future-market-report-coming-2018/">our report</a> and reach out. Thanks for reading!</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=6707184d4600" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[The intersection of lifesciences, business and tech]]></title>
            <link>https://medium.com/@mikastefanie/the-intersection-of-lifesciences-business-and-tech-532c6383f091?source=rss-e928e5144b97------2</link>
            <guid isPermaLink="false">https://medium.com/p/532c6383f091</guid>
            <category><![CDATA[programming]]></category>
            <category><![CDATA[hiring]]></category>
            <category><![CDATA[reactjs]]></category>
            <category><![CDATA[biotechnology]]></category>
            <category><![CDATA[jobs]]></category>
            <dc:creator><![CDATA[Mika Wang 王美华]]></dc:creator>
            <pubDate>Mon, 12 Nov 2018 23:07:22 GMT</pubDate>
            <atom:updated>2018-11-12T23:07:22.212Z</atom:updated>
            <content:encoded><![CDATA[<h4>… is where your next role may be waiting</h4><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*DVJesaXIUACA1HUUI8vrQQ.png" /><figcaption>You?</figcaption></figure><p>If working at the intersection of three high growth, high impact industries excites you or someone you know, please take a look at our job posting below.</p><h4>Who We Are</h4><p>DeciBio provides market and competitive intelligence tools to help clients track, analyze, and act on everything happening in the fast evolving lifesciences space. We believe there is huge whitespace in collecting intelligence data (e.g., publications, clinical abstracts) to drive actionable insights and business opportunities. Marketing and sales teams can gain significant leverage by systematically ingesting large datasets from their external environment and mining that data for actionable intel.</p><p>We are passionate about bringing lifesciences, business and tech people together to create significant value at the nexus of these industries. Our brilliant team works hard yet values diverse perspectives as we believe this yields better results for our clients, a more interesting workplace, and a supportive and collaborative culture.</p><p>We have an open, casual, and upbeat work environment with limitless opportunities to take initiative and make an impact. We offer an opportunity to be an integral part of a young and fast-growing company, participate in its growth, and expand your functional role.</p><h4>DeciBio Engineering</h4><p>As part of our growing product team, you will be responsible for building and maintaining the tools and infrastructure that enable our existing clients to track their competitors by monitoring their digital footprint.</p><p>As a full-stack engineer with 2+ years of experience, you can expect to develop features using modern frameworks and stacks including React, MongoDB, JS, MERN stack (MongoDB, Express, React, Node.js) and various amazon web services (AWS). You will work alongside lifesciences subject matter experts, data analysts, product managers, and sales and marketing and will be engaged in the end-to-end process of delivering a high quality product. You will have the opportunity to meet with our existing clients and users, hear product feedback and contribute to the overall architecture and maintenance of our software systems. Depending on the level of experience, you will also play a significant role in hiring and developing junior developers, front-end engineers and UX designers.</p><h4>DeciBio’s Core Values</h4><p>We are looking for a back-end engineer who embodies our values, including:</p><p>• Entrepreneurial. You are willing to break free from convention by learning to take smart risks and constantly innovate. <br>• Collaborative &amp; Supportive. You are willing to push your colleagues to achieve beyond expectations while supporting one another in times of failure. <br>• Thought-Leadership. You stay abreast of trends and best practices in programming and are sought out for your opinion, even if others do not immediately agree with you. <br>• Grit / Hunger. Even in the face of obstacles, you carry a smile on your face and a fire in your belly. <br>• Transparency. You instill openness by creating a culture of trust and nurturing authentic relationships. <br>• Balanced / Holistic. You live a balanced, holistic life enabling you to be creative, energetic and happy at work. <br>• Honorable. You do the right thing, and you treat others with respect.</p><h4>Qualifications</h4><p>• Minimum of 2 years of industry experience in full-stack development. <br>• Fluent in at least one major programming language (e.g., react.js). <br>• Experience archetecting and implementing reliable web applications and distributed systems. <br>• Strong knowledge of database fundamentals. <br>• Experience with data science ML frameworks is a plus. <br>• Experience at early-stage startups is a large plus.</p><p>More on DeciBio <a href="http://decibio.com/">here</a> and the original job posting <a href="https://angel.co/decibio-consulting/jobs/457217-backend-full-stack-developer">here</a>.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=532c6383f091" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Three lessons for digital health entrepreneurs from those who have been there]]></title>
            <link>https://medium.datadriveninvestor.com/three-lessons-for-digital-health-entrepreneurs-from-those-who-have-been-there-f6aff92f6514?source=rss-e928e5144b97------2</link>
            <guid isPermaLink="false">https://medium.com/p/f6aff92f6514</guid>
            <category><![CDATA[entrepreneurship]]></category>
            <category><![CDATA[healthcare]]></category>
            <category><![CDATA[health-technology]]></category>
            <category><![CDATA[digital-health]]></category>
            <dc:creator><![CDATA[Mika Wang 王美华]]></dc:creator>
            <pubDate>Wed, 31 Oct 2018 03:20:12 GMT</pubDate>
            <atom:updated>2018-11-01T02:03:55.675Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*1TGIEx4MrWEo4Q_U" /><figcaption>“red apple on white surface” by <a href="https://unsplash.com/@taradee?utm_source=medium&amp;utm_medium=referral">Terra Evans</a> on <a href="https://unsplash.com/?utm_source=medium&amp;utm_medium=referral">Unsplash</a></figcaption></figure><p>This year’s Rock Health annual digital health summit (#RHSUM18) showcased another impressive lineup with speakers like Bernard Tyson (CEO of Kaiser Permanente), Toby Cosgrove (former CEO of Cleveland Clinic and current Executive Adviser to Google Cloud), Anne Wojcicki (Founder and CEO of 23andMe) and Ali Diab (Co-founder/CEO of Collective Health) in attendance, among many others. Below <a href="https://www.decibio.com/2018/10/31/rock-health-oct-2018/">we</a> highlight critical lessons for digital health entrepreneurs, and <a href="https://www.linkedin.com/pulse/rhsum-2017-takeaways-mika-wang/">here</a> we chronicle takeaways from last year’s conference.</p><h4>#1: SOLVE THE PROBLEMS THAT AFFECT MOST PEOPLE</h4><p>In the U.S. today, ~60% of cancer patients rely on Medicare, while ~40% of pregnancies are financed by Medicaid.</p><blockquote>To make an impact in healthcare, don’t build solutions for Google and Amazon employees. Design solutions that solve problems for those who need it most.</blockquote><blockquote>What does this mean for digital health entrepreneurs? Understand your intended audience and their unique challenges: find out what language your patient population consumes content in (hint: maybe it’s not English), identify where your patient population consumes content (hint: it may be Android over Apple) and recognize when your patient population consumes content (hint: it may be on a limited data plan).</blockquote><p>Leah Sparks, Founder and CEO of Wildflower Health, credits these unique insights for enabling and empowering Wildflower’s patient population (i.e., Medicaid mothers) to become “power users,” logging into Wildflower’s app more often than mothers covered by commercial payers.</p><p><strong>#2: COMBAT FAUX SCIENCE LIKE YOU FIGHT FAKE NEWS</strong></p><p>According to <a href="https://rockhealth.com/reports/2017-year-end-funding-report-the-end-of-the-beginning-of-digital-health/">data from Rock Health</a>, digital health investments have grown at a healthy CAGR of 29% over the past 4 years. One downside to this growth is the explosion of new direct-to-consumer (DTC) companies making health claims yet to be evaluated (if ever) by our regulatory bodies, namely the FDA. Anne Wojcicki, who is <a href="https://www.nature.com/news/the-rise-and-fall-and-rise-again-of-23andme-1.22801">no stranger to FDA regulations</a>, warned against entrepreneurs trying to bypass and/or otherwise circumvent the federal agency. Wojcicki pointed to the rise of companies like Gwyneth Paltrow’s <a href="http://goop.com/">Goop Health</a> (among many others — who knew <a href="https://medium.com/s/story/why-have-our-offices-become-like-touchy-feely-kindergartens-cc7629912fb7">Lego Serious Play</a> was a real thing?) that make unsubstantiated health claims. At best, these companies spread pseudoscience that murky the waters of science backed by peer-reviewed publications, clinical trials and/or regulatory approval. At worst, these companies could <a href="https://www.cnbc.com/2018/10/29/gwyneth-paltrows-goop-reported-to-uk-watchdogs-overadvertising.html">harm consumers</a>.</p><blockquote>What does this mean for digital health entrepreneurs? Demonstrate analytical and clinical validity required to gain regulatory approval with the relevant body (e.g., FDA in the U.S., CNDA in China, NICE in the UK) and, better yet, show clinical utility in order to achieve widespread coverage for your product. Are you developing an app or clinical algorithm? At least in the U.S., the FDA now has a Digital Health Software Precertification Program for regulating software as a medical device (SaMD).</blockquote><p><strong>#3: FOCUS ON THE TRIPLE THREAT TO GAIN TRACTION</strong></p><p>One major theme at this year’s conference was the need for digital solutions to improve the unsexy or operational aspects of care. From voice recognition software to “smart” fast-track ques to digital triage, opportunities abound to decrease costs and increase efficiency while at the same time improving the quality of care. As Toby Cosgrove, executive adviser of Cleveland Clinic and Google Cloud noted, “20% of hospitals are running in the red and even the most profitable have only a 3% margin. There are screaming needs in the delivery of care.”</p><blockquote>What does this mean for digital health entrepreneurs? If you are developing advanced AI or machine-learning algorithms, great. But focus your solution around the so-called triple threat: one that decreases cost, increases efficiency and improves outcomes. Direct your solutions towards reducing some of that administrative burden that <a href="https://www.theatlantic.com/health/archive/2018/05/the-burnout-crisis-in-health-care/559880/">keeps healthcare providers squeezed</a>. Win back some time, and you will be rewarded (with traction).</blockquote><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=f6aff92f6514" width="1" height="1" alt=""><hr><p><a href="https://medium.datadriveninvestor.com/three-lessons-for-digital-health-entrepreneurs-from-those-who-have-been-there-f6aff92f6514">Three lessons for digital health entrepreneurs from those who have been there</a> was originally published in <a href="https://medium.datadriveninvestor.com/">DataDrivenInvestor</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Michael from Houston, TX]]></title>
            <link>https://medium.com/@mikastefanie/michael-from-houston-tx-f3df6ef227b?source=rss-e928e5144b97------2</link>
            <guid isPermaLink="false">https://medium.com/p/f3df6ef227b</guid>
            <category><![CDATA[los-angeles]]></category>
            <category><![CDATA[homeless]]></category>
            <category><![CDATA[humanity]]></category>
            <category><![CDATA[houston]]></category>
            <category><![CDATA[homelessness]]></category>
            <dc:creator><![CDATA[Mika Wang 王美华]]></dc:creator>
            <pubDate>Sat, 27 Oct 2018 21:17:11 GMT</pubDate>
            <atom:updated>2018-10-27T21:17:11.440Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*A7M02rE5eKJJQfkCBXM-4g.jpeg" /><figcaption>Meet Michael, 56 years old, who lives on the streets in Houston not far from the hotel we were staying at while attending a good friend’s wedding</figcaption></figure><p>Michael used to own two houses. Hurricane Harvey took one; Michael’s inability to pay taxes and eventual foreclosure took the other. His family lives in DC, though he grew up in Houston. His father was a veteran. Beacon, a nearby halfway home, gives him a place to sleep, access to doctors who prescribe his medications, and a washer to clean his clothes. He believes deeply in the power of God. He also believes his homelessness is God’s way of reminding him that he is blessed, as he says he was on ‘our side’ of the homelessness coin once, looking down at those who begged for help. These are Michael’s facts, but are hardly the full picture.</p><p>According to <a href="http://www.homelesshouston.org/coalition-faq/how-many-people-are-homeless-in-the-houston-area/">data from 2014</a>, 1 in 500 people live in homelessness in Houston. This <a href="https://earther.gizmodo.com/houstons-homeless-population-has-spiked-since-hurricane-1826290888">number jumps</a> after natural disasters like Hurricane Harvey hit, and its often those who are most vulnerable — people of color, low-income families, children, elderly, disabled — who get hit hardest. In Los Angeles, where I live, the data paints an even grimmer picture. Over 57,000 people lack a “fixed, regular or adequate place to sleep” on any given night in the county. With a population of 4,000,000 (2017), this means more than 1 in 100 experience homelessness each night. In a city that some of the wealthiest people in the world call home. And it’s <a href="http://www.latimes.com/local/lanow/la-me-homeless-how-we-got-here-20180201-story.html">getting worse</a>.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*6SvNLl8odFRIdU8s" /></figure><p>I was surprised to learn that LA is one of the bottom feeders when it comes to housing unsheltered homeless:</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*1XUqoWi-qIe26uqq.png" /></figure><p>There’s clearly no easy answer (or even one way) to solving this problem. Collecting data to understand and solve the problem, or supporting those <a href="https://www.huduser.gov/portal/periodicals/em/summer12/highlight2.html#title">organizations who do</a>, is one step towards untangling this intricate knot. Another, one that any one can do, is to choose to recognize the issue. To see the face — faces — that sleep on the streets, to try to understand why and how this happened.</p><blockquote>As Michael in Houston reminded us, “take one day at a time. You never know what tomorrow will bring. Just put one foot in front of the other, until you’re back on the other side”</blockquote><p>This is one of the toughest problems of our generation. This also makes it a problem worth our time figuring out how to solve.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=f3df6ef227b" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Chinese Equivalents to Popular U.S. Apps]]></title>
            <link>https://medium.com/@mikastefanie/chinese-equivalents-to-popular-u-s-apps-39cd4c429dcc?source=rss-e928e5144b97------2</link>
            <guid isPermaLink="false">https://medium.com/p/39cd4c429dcc</guid>
            <category><![CDATA[apps]]></category>
            <category><![CDATA[life-hacking]]></category>
            <category><![CDATA[travel-tips]]></category>
            <category><![CDATA[china]]></category>
            <dc:creator><![CDATA[Mika Wang 王美华]]></dc:creator>
            <pubDate>Thu, 13 Sep 2018 03:48:58 GMT</pubDate>
            <atom:updated>2018-09-18T11:18:27.794Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*tpF8nt8N1QryzRw93vcaGQ.jpeg" /><figcaption>Looking for the best local food? There’s an (unblocked) app for that:<a href="http://www.meituan.com/">美团</a></figcaption></figure><p>As of <a href="https://startuplivingchina.com/list-websites-apps-blocked-china/">August 2018</a>, the following popular U.S. social media websites / productivity / messaging / email apps are blocked in China:</p><ul><li>Google suite (Gmail, Hangouts, Drive, Docs, Google+)</li><li>Dropbox</li><li>Slack</li><li>YouTube</li><li>Netflix</li><li>LINE</li><li>Twitter</li><li>Facebook / Instagram</li><li>Snapchat</li><li>Pinterest</li><li>etc.</li></ul><p>If you are anything like I was when I <a href="https://awanginchina.tumblr.com/post/125068475333/first-post-im-alive-%E7%AC%AC%E4%B8%80%E7%AF%87%E7%9A%84%E5%8D%9A%E5%AE%A2%E6%96%87%E7%AB%A0-%E6%88%91%E8%BF%98%E6%B2%A1%E6%AD%BB%E4%BA%86?is_related_post=1">first moved to China</a>, you are probably wondering how you will get any work done without Gmail, Dropbox and Slack and how you will be distracted from work without Instagram, Snapchat, Facebook and Twitter. Before racing to the nearest WiFi cafe (<em>note: fast WiFi is a rarity outside Tier 1 cities</em>) and jumping on a VPN, take a look of these unblocked, local and frequently used Chinese apps (“A-P-Ps”).</p><h3>A starter set of apps for your Chinese phone</h3><p><em>(must-haves in </em><strong><em>bold</em></strong><em>)</em></p><p><strong>Information/Productivity:</strong></p><p>Google (search) &lt;=&gt; <a href="http://baidu.com/">Baidu</a></p><p>Gmail &lt;=&gt; <a href="http://163.com/">163.com</a>, <a href="http://yeah.net/">Yeah.net</a></p><p>Google Maps &lt;=&gt; <a href="http://map.baidu.com/">百度地图</a></p><p>Google Translate &lt;=&gt; <a href="https://fanyi.baidu.com/"><strong>Baidu Fanyi</strong></a>, <a href="https://www.pleco.com/"><strong>Pleco</strong></a></p><p>Dropbox/Box &lt;=&gt; Alibaba Cloud (<a href="http://cn.aliyun.com/">Aliyun</a>), <a href="https://www.jianguoyun.com/">Nutstore</a></p><p>Asana/Slack &lt;=&gt; <a href="http://teambition.com/">Teambition</a>, <a href="http://trello.com/"><strong>Trello</strong></a></p><p><strong>E-Commerce/Shopping:</strong></p><p>Amazon &lt;=&gt; <a href="http://taobao.com/"><strong>Taobao</strong></a></p><p>Gilt / Clothing / Fashion&lt;=&gt; <a href="http://tmall.com/"><strong>Tmall</strong></a></p><p><strong>Social Media / Messaging:</strong></p><p>Instagram &lt;=&gt; MaoPaoPaiPai, Tuitu, Mzpai or YouTu</p><p>Facebook &lt;=&gt; WeChat, 人人</p><p>MSN &lt;=&gt; <a href="https://t.umblr.com/redirect?z=http%3A%2F%2Fqq.com&amp;t=YTRhM2NhZDgwM2JiN2E0MWEzYjgwZWVhZDZkMmE2YWMwZmQ4YWI0MCxKTlJ5ZzVEQw%3D%3D&amp;b=t%3Aaf2GUw_sQ57-YFtAMCLrXw&amp;p=https%3A%2F%2Fawanginchina.tumblr.com%2Fpost%2F137610593043%2Fchinese-equivalents-to-popular-us-appswebsites&amp;m=1">QQ</a> (plays a similar role to Slack in the office)</p><p>Pinterest &lt;=&gt; FaXian (fashion), Huaban (general)</p><p>Twitter, Reddit&lt;=&gt; Weibo</p><p>YouTube &lt;=&gt; <a href="https://t.umblr.com/redirect?z=http%3A%2F%2Fyouku.com&amp;t=ZGMzZGY0OTdiY2UyYTVkZTY5ZjIyNjA1NjY1ZmJkN2I3YmQ4OTk5OCxKTlJ5ZzVEQw%3D%3D&amp;b=t%3Aaf2GUw_sQ57-YFtAMCLrXw&amp;p=https%3A%2F%2Fawanginchina.tumblr.com%2Fpost%2F137610593043%2Fchinese-equivalents-to-popular-us-appswebsites&amp;m=1">Youku</a></p><p><strong>Food / Delivery:</strong></p><p>Doordash &lt;=&gt; <strong>美团外卖</strong></p><p>Yelp &lt;=&gt; <strong>美团</strong></p><p><strong>Finance:</strong></p><p>Mint &lt;=&gt; <a href="https://t.umblr.com/redirect?z=http%3A%2F%2Fwww.51xiaofu.com&amp;t=NWRjZmZiZjA5MzE4ZDI5OWZiZGMwZGZlYzczMDgxM2NlYTVhMDAwOCxKTlJ5ZzVEQw%3D%3D&amp;b=t%3Aaf2GUw_sQ57-YFtAMCLrXw&amp;p=https%3A%2F%2Fawanginchina.tumblr.com%2Fpost%2F137610593043%2Fchinese-equivalents-to-popular-us-appswebsites&amp;m=1">51xiaofu</a></p><p>Venmo &lt;=&gt; <strong>Alipay</strong>, Zhifubao, <strong>WeChat</strong></p><p><strong>Travel/Transportation:</strong></p><p>AirBnb &lt;=&gt; <a href="https://www.tumblr.com/edit/tujia.com">Tujia</a>, Airbnb</p><p>Craigslist &lt;=&gt; <a href="https://www.tumblr.com/edit/ganji.com">Ganji.com</a></p><p>LiveLovely/Zumper/Apt Hunting &lt;=&gt; Ganji.com, <a href="https://www.tumblr.com/edit/58.com">58.com</a>, <a href="https://www.tumblr.com/edit/zhantai.com">Zhantai.com</a></p><p>Lyft/Uber &lt;=&gt; <strong>快的打车</strong></p><p><strong>Lifestyle/Entertainment:</strong></p><p>Groupon/LiveSocial &lt;=&gt; Gaopeng, Tuangou, Meituan</p><p>SoundCloud/Spotify &lt;=&gt; <strong>QQ音乐</strong> (nice app similar to Spotify with Chinese music)</p><p>Rotten Tomato / Reddit &lt;=&gt; <a href="http://douban/"><strong>Douban</strong></a></p><p>Quora &lt;=&gt; <a href="http://zhihu.com/">Zhihu</a></p><p><strong>Healthcare</strong>:</p><p>ZocDoc &lt;=&gt; FindDoc (HK)</p><p>Teladoc &lt;=&gt; <a href="https://www.chunyuyisheng.com/">Chunyu Yisheng</a></p><p><em>What Chinese apps do you use most? Let me know what I missed!</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=39cd4c429dcc" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>